Investigating the Impact of Optimized -Cinnamic Acid-Loaded PLGA Nanoparticles on Epithelial to Mesenchymal Transition in Breast Cancer

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2022 Feb 25

PMID 35210772

Authors

Noha M Badawi

Yasmeen M Attia

Dina M El-Kersh

Olfat A Hammam

Maha K A Khalifa

Affiliations

Soon will be listed here.

Abstract

Purpose: To design and optimize -cinnamic acid-loaded PLGA nanoparticles (CIN-PLGA-NPs) and assess its inhibitory effect on epithelial-mesenchymal transition (EMT) in triple-negative breast cancer.

Methods: The quality by design approach was used to correlate the formulation parameters (PLGA amount and Poloxamer188 concentration) and critical quality attributes (entrapment efficiency percent, particle size and zeta potential). Design of CIN-PLGA-NPs formulations was done based on central composite response surface design and formulated by nanoprecipitation method. In addition, the optimized CIN-PLGA-NPs formulation was further evaluated for morphology using transmission electron microscopy and in vitro dissolution test. The cytotoxicity of CIN-PLGA-NPs optimized formula in comparison to the free -cinnamic acid (CIN-Free) was investigated in vitro using MDA-MB-231, triple-negative breast cancer cells, followed by scratch wound assay for evaluating the impact on the migratory potential of MDA-MB-231 cells. In vivo antitumor activity was evaluated using Ehrlich ascites carcinoma solid tumor animal model where tumor volumes were measured at different time points and necrotic/apoptotic indices were estimated in tumor sections. EMT markers, E- and N-cadherin, were assessed in solid tumors as well.

Results: The optimized formulation showed entrapment efficiency of 76.98%, particle size of 186.3 nm with a smooth spherical surface and zeta potential of -28.47 mV indicating its stability. Furthermore, CIN-PLGA-NPs optimized formula released 60.8±1.89% of the total CIN-Free within 24 hours compared to 29±1.25% of the raw CIN-Free indicating improved dissolution rate. The optimized formula showed superior cytotoxicity on MDA-MB-231 cells compared to its free counterpart as well as increased wound closure percentage along with reduced tumor size in mice and increased necrotic and apoptotic indices. Tumor levels of E-cadherin and N-cadherin were indicative of EMT inhibition.

Conclusion: Our findings proved the capability of PLGA nanoparticles in loading -cinnamic acid in addition to enhancing its antitumor efficacy in triple-negative breast cancer possibly via inhibiting EMT.

Citing Articles

Production of Prophylactic Nanoformulation for Dental Caries and Investigation of Its Effectiveness by In Vitro and In Silico Methods.

Budama-Kilinc Y, Kurtur O, Gok B, Kecel-Gunduz S, Alpay-Karaoglu S, Yilmaz Atali P Pharmaceutics. 2025; 17(2).

PMID: 40006534 PMC: 11859156. DOI: 10.3390/pharmaceutics17020167.

Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications.

Ceylan F, Gunal-Koroglu D, Saricaoglu B, Ozkan G, Capanoglu E, Calina D Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):469-495.

PMID: 39212736 DOI: 10.1007/s00210-024-03396-x.

Recent Advances of Multifunctional PLGA Nanocarriers in the Management of Triple-Negative Breast Cancer.

Dinakar Y, Rajana N, Kumari N, Jain V, Mehra N AAPS PharmSciTech. 2023; 24(8):258.

PMID: 38097825 DOI: 10.1208/s12249-023-02712-7.

Enhancing the anticancer potential of metformin: fabrication of efficient nanospanlastics, cytotoxic studies on HEP-2 cells and reactome enhanced pathway analysis.

Raafat S, Abd El Wahed S, Badawi N, Saber M, Abdollah M Int J Pharm X. 2023; 6:100215.

PMID: 38024451 PMC: 10630776. DOI: 10.1016/j.ijpx.2023.100215.

Development, Optimization, and In Vitro/In Vivo Evaluation of Azelaic Acid Transethosomal Gel for Antidermatophyte Activity.

Nasr A, Badawi N, Tartor Y, Sobhy N, Swidan S Antibiotics (Basel). 2023; 12(4).

PMID: 37107069 PMC: 10135108. DOI: 10.3390/antibiotics12040707.

References

Anwer M, Mohammad M, Ezzeldin E, Fatima F, Alalaiwe A, Iqbal M . Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats. Int J Nanomedicine. 2019; 14:1587-1595. PMC: 6402442. DOI: 10.2147/IJN.S195048. View

Jaganathan S, Mondhe D, Wani Z, Pal H, Mandal M . Effect of honey and eugenol on Ehrlich ascites and solid carcinoma. J Biomed Biotechnol. 2010; 2010:989163. PMC: 2846731. DOI: 10.1155/2010/989163. View

Zhang Y, Xu Y, Zhang S, Zhao J, Wang Z, Xu D . In vivo microdialysis for the evaluation of transfersomes as a novel transdermal delivery vehicle for cinnamic acid. Drug Dev Ind Pharm. 2013; 40(3):301-7. DOI: 10.3109/03639045.2012.756888. View

de Aquino F, Silva J, Ferro J, Lagente V, Barreto E . trans-Cinnamic acid, but not p-coumaric acid or methyl cinnamate, induces fibroblast migration through PKA- and p38-MAPK signalling pathways. J Tissue Viability. 2021; 30(3):363-371. DOI: 10.1016/j.jtv.2021.05.003. View

El-Kersh D, Ezzat S, Salama M, Mahrous E, Attia Y, Ahmed M . Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer. Sci Rep. 2021; 11(1):7121. PMC: 8007834. DOI: 10.1038/s41598-021-86599-z. View

De Vita A, Liverani C, Molinaro R, Martinez J, Hartman K, Spadazzi C . Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. Sci Rep. 2021; 11(1):5107. PMC: 7930284. DOI: 10.1038/s41598-021-84492-3. View

Ahmad N, Alam M, Ahmad R, Naqvi A, Ahmad F . Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer. Artif Cells Nanomed Biotechnol. 2017; 46(2):432-446. DOI: 10.1080/21691401.2017.1324466. View

Chowdhury P, Ghosh U, Samanta K, Jaggi M, Chauhan S, Yallapu M . Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioact Mater. 2021; 6(10):3269-3287. PMC: 7970221. DOI: 10.1016/j.bioactmat.2021.02.037. View

Xu X, Zhang L, He X, Zhang P, Sun C, Xu X . TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochem Biophys Res Commun. 2018; 502(1):160-165. DOI: 10.1016/j.bbrc.2018.05.139. View

10.

Al-Jubori A, Sulaiman G, Tawfeeq A, Mohammed H, Khan R, Mohammed S . Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment. Pharmaceutics. 2021; 13(7). PMC: 8309206. DOI: 10.3390/pharmaceutics13071098. View

11.

Haggag Y, Abosalha A, Tambuwala M, Osman E, El-Gizawy S, Essa E . Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity. Biopharm Drug Dispos. 2020; 42(1):12-23. PMC: 7898708. DOI: 10.1002/bdd.2255. View

12.

Nasr A, Elhady S, Swidan S, Badawi N . Celecoxib Loaded In-Situ Provesicular Powder and Its In-Vitro Cytotoxic Effect for Cancer Therapy: Fabrication, Characterization, Optimization and Pharmacokinetic Evaluation. Pharmaceutics. 2020; 12(12). PMC: 7760804. DOI: 10.3390/pharmaceutics12121157. View

13.

Pal A, Tapadar P, Pal R . Exploring the Molecular Mechanism of Cinnamic Acid-Mediated Cytotoxicity in Triple Negative MDA-MB-231 Breast Cancer Cells. Anticancer Agents Med Chem. 2020; 21(9):1141-1150. DOI: 10.2174/1871520620666200807222248. View

14.

Brigger I, Dubernet C, Couvreur P . Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54(5):631-51. DOI: 10.1016/s0169-409x(02)00044-3. View

15.

Pandit J, Sultana Y, Aqil M . Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Artif Cells Nanomed Biotechnol. 2016; 45(7):1397-1407. DOI: 10.1080/21691401.2016.1243545. View

16.

Yuan Y, Cai T, Xia X, Zhang R, Chiba P, Cai Y . Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer. Drug Deliv. 2016; 23(9):3350-3357. DOI: 10.1080/10717544.2016.1178825. View

17.

Mohammadi G, Valizadeh H, Barzegar-Jalali M, Lotfipour F, Adibkia K, Milani M . Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf B Biointerfaces. 2010; 80(1):34-9. DOI: 10.1016/j.colsurfb.2010.05.027. View

18.

Khaled N, Bidet Y . New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer. Cancers (Basel). 2019; 11(4). PMC: 6521131. DOI: 10.3390/cancers11040559. View

19.

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

20.

Du B, Shim J . Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016; 21(7). PMC: 6273543. DOI: 10.3390/molecules21070965. View